0HB0.L
Agios Pharmaceuticals, Inc. [0HB0.L] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0HB0.L Stock Summary
Top 10 Correlated ETFs
0HB0.L
Top 10 Correlated Stocks
0HB0.L
In the News
0HB0.L Financial details
Company Rating
Sell
Market Cap
1.66B
Income
-352.09M
Revenue
26.82M
Book val./share
14.51
Cash/share
13.9
Dividend
-
Dividend %
-
Employees
383
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-6.02
Forward P/E
-
PEG
-1.21
P/S
55.08
P/B
1.49
P/C
2.09
P/FCF
-4.55
Quick Ratio
11.1
Current Ratio
12.06
Debt / Equity
0.02
LT Debt / Equity
-
-
-
EPS (TTM)
-6.34
EPS next Y
-
EPS next Q
-
EPS this Y
49.65%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.6%
Revenue last 5Y
-25.63%
Revenue Q/Q
-4%
EPS Q/Q
4.88%
-
-
-
-
SMA20
-
SMA50
30.43%
SMA100
36.36%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-22%
ROC
-0.41%
Gross Margin
-1687%
Oper. Margin
-1600%
Profit Margin
-914%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.13-35.3493
52W High
-16.86%
52W Low
+45.5%
RSI
50
Rel Volume
-
Avg Volume
522
Volume
2
Perf Week
-0.55%
Perf Month
-7.53%
Perf Quarter
36.94%
Perf Half Y
25.49%
-
-
-
-
Beta
0.855
-
-
Volatility
0.48%, 0.99%
Prev Close
-0.55%
Price
29.1
Change
-
0HB0.L Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.97 | 0 | 0 | 0.26 | 0.48 | |
| Net income per share | -6.86 | -4.74 | -6.36 | -4.23 | -6.33 | |
| Operating cash flow per share | -6.18 | -4.21 | -6.74 | -5.65 | -5.32 | |
| Free cash flow per share | -6.38 | -4.42 | -6.83 | -5.74 | -5.34 | |
| Cash per share | 9.42 | 8.3 | 16.87 | 14.29 | 13.96 | |
| Book value per share | 10.68 | 5.79 | 21.37 | 20.09 | 14.57 | |
| Tangible book value per share | 10.68 | 5.79 | 21.37 | 20.09 | 14.57 | |
| Share holders equity per share | 10.68 | 5.79 | 21.37 | 20.09 | 14.57 | |
| Interest debt per share | 0.12 | 0.37 | 0.18 | 0.25 | 0.27 | |
| Market cap | 3.14B | 3.11B | 2.04B | 1.68B | 1.25B | |
| Enterprise value | 3.18B | 3.08B | 1.93B | 1.63B | 1.23B | |
| P/E ratio | -7.64 | -9.49 | -5.31 | -7.26 | -3.54 | |
| Price to sales ratio | 26.66 | 0 | 0 | 118.24 | 46.47 | |
| POCF ratio | -8.48 | -10.69 | -5.01 | -5.44 | -4.21 | |
| PFCF ratio | -8.21 | -10.19 | -4.94 | -5.36 | -4.2 | |
| P/B Ratio | 4.91 | 7.78 | 1.58 | 1.53 | 1.54 | |
| PTB ratio | 4.91 | 7.78 | 1.58 | 1.53 | 1.54 | |
| EV to sales | 26.94 | 0 | 0 | 114.48 | 45.87 | |
| Enterprise value over EBITDA | -7.75 | -9.73 | -5.38 | -4.4 | -3.2 | |
| EV to operating cash flow | -8.57 | -10.61 | -4.75 | -5.27 | -4.16 | |
| EV to free cash flow | -8.3 | -10.12 | -4.68 | -5.19 | -4.14 | |
| Earnings yield | -0.13 | -0.11 | -0.19 | -0.14 | -0.28 | |
| Free cash flow yield | -0.12 | -0.1 | -0.2 | -0.19 | -0.24 | |
| Debt to equity | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Net debt to EBITDA | -0.08 | 0.07 | 0.29 | 0.14 | 0.04 | |
| Current ratio | 6.59 | 6.74 | 17.79 | 13.3 | 12.27 | |
| Interest coverage | 0 | -18.84 | 0 | 0 | 0 | |
| Income quality | 0.9 | 0.88 | 1.14 | 1.34 | 0.84 | |
| Dividend Yield | 0 | 0 | 0.38 | 0 | 0 | |
| Payout ratio | 0 | 0 | -1.99 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 3.42 | 0 | 0 | 19.06 | 10.77 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.05 | 0.01 | 0.02 | 0 | |
| Capex to revenue | -0.1 | 0 | 0 | -0.34 | -0.04 | |
| Capex to depreciation | -0.73 | -0.75 | -0.31 | -0.26 | -0.15 | |
| Stock based compensation to revenue | 0.49 | 0 | 0 | 3.46 | 0 | |
| Graham number | 40.59 | 24.86 | 55.3 | 43.73 | 45.55 | |
| ROIC | -0.57 | -0.66 | -0.29 | -0.33 | -0.44 | |
| Return on tangible assets | -0.46 | -0.38 | -0.27 | -0.19 | -0.38 | |
| Graham Net | 5.5 | 1.73 | 14.52 | 11.88 | 11.9 | |
| Working capital | 518.82M | 542.28M | 1B | 770.14M | 765.88M | |
| Tangible asset value | 640.53M | 399.5M | 1.29B | 1.1B | 811.02M | |
| Net current asset value | 361.49M | 183.23M | 918.47M | 694.87M | 707.74M | |
| Invested capital | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Average receivables | 12.88M | 7.66M | 2.19M | 3.29M | 2.51M | |
| Average payables | 19.89M | 19.81M | 17.21M | 17.66M | 14.2M | |
| Average inventory | 4.1M | 3.67M | 0 | 4.25M | 13.78M | |
| Days sales outstanding | 47.42 | 0 | 0 | 56.54 | 38.24 | |
| Days payables outstanding | 445.59 | 344.62 | 324.63 | 335.33 | 375.6 | |
| Days of inventory on hand | 149.19 | 0 | 0 | 152.97 | 732.61 | |
| Receivables turnover | 7.7 | 0 | 0 | 6.46 | 9.55 | |
| Payables turnover | 0.82 | 1.06 | 1.12 | 1.09 | 0.97 | |
| Inventory turnover | 2.45 | 0 | 0 | 2.39 | 0.5 | |
| ROE | -0.64 | -0.82 | -0.3 | -0.21 | -0.43 | |
| Capex per share | -0.2 | -0.2 | -0.09 | -0.09 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.08 | 0.1 | 0.12 | 0.13 | 0.13 | |
| Net income per share | 0.66 | -1.47 | -1.51 | -1.64 | -1.72 | |
| Operating cash flow per share | -1.2 | -1.72 | -1.2 | -1.1 | -1.3 | |
| Free cash flow per share | -1.2 | -1.73 | -1.2 | -1.11 | -1.3 | |
| Cash per share | 14.23 | 13.38 | 12.64 | 11.6 | 13.9 | |
| Book value per share | 20 | 18.76 | 17.34 | 15.89 | 14.51 | |
| Tangible book value per share | 20 | 18.76 | 17.34 | 15.89 | 14.51 | |
| Share holders equity per share | 20 | 18.76 | 17.34 | 15.89 | 14.51 | |
| Interest debt per share | 0.25 | 0.25 | 0.26 | 0.26 | 0.27 | |
| Market cap | 1.69B | 1.28B | 1.62B | 1.39B | 1.25B | |
| Enterprise value | 1.64B | 1.26B | 1.61B | 1.4B | 1.24B | |
| P/E ratio | 11.58 | -3.96 | -4.83 | -3.81 | -3.26 | |
| Price to sales ratio | 392.45 | 228.88 | 241.07 | 188.33 | 176.28 | |
| POCF ratio | -25.56 | -13.49 | -24.24 | -22.6 | -17.27 | |
| PFCF ratio | -25.52 | -13.43 | -24.24 | -22.47 | -17.22 | |
| P/B Ratio | 1.54 | 1.24 | 1.68 | 1.57 | 1.54 | |
| PTB ratio | 1.54 | 1.24 | 1.68 | 1.57 | 1.54 | |
| EV to sales | 380.01 | 225 | 240.21 | 189.83 | 174 | |
| Enterprise value over EBITDA | -17.28 | -14.64 | -18.07 | -14.15 | -11.78 | |
| EV to operating cash flow | -24.75 | -13.26 | -24.15 | -22.79 | -17.05 | |
| EV to free cash flow | -24.71 | -13.2 | -24.16 | -22.65 | -16.99 | |
| Earnings yield | 0.02 | -0.06 | -0.05 | -0.07 | -0.08 | |
| Free cash flow yield | -0.04 | -0.07 | -0.04 | -0.04 | -0.06 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Net debt to EBITDA | 0.57 | 0.25 | 0.07 | -0.11 | 0.15 | |
| Current ratio | 13.3 | 17.55 | 13.73 | 12.06 | 12.27 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | -1.81 | 1.17 | 0.8 | 0.67 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 15.89 | 11.68 | 10 | 10.84 | 10.71 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | -0.03 | -0.07 | 0 | -0.05 | -0.03 | |
| Capex to depreciation | -0.03 | -0.09 | 0 | -0.23 | -0.17 | |
| Stock based compensation to revenue | 2.66 | 1.81 | 1.75 | 1.23 | 0 | |
| Graham number | 17.28 | 24.87 | 24.25 | 24.19 | 23.67 | |
| ROIC | -0.08 | -0.08 | -0.09 | -0.1 | -0.12 | |
| Return on tangible assets | 0.03 | -0.07 | -0.08 | -0.09 | -0.1 | |
| Graham Net | 11.83 | 11.43 | 10.63 | 9.62 | 11.85 | |
| Working capital | 770.14M | 746.54M | 702.1M | 645.93M | 765.88M | |
| Tangible asset value | 1.1B | 1.04B | 964.24M | 886.84M | 811.02M | |
| Net current asset value | 694.87M | 676.88M | 636.32M | 583.94M | 707.74M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Average receivables | 3.9M | 1.99M | 2.01M | 1.71M | 1.99M | |
| Average payables | 14.52M | 13.64M | 10.14M | 12.45M | 11.53M | |
| Average inventory | 6.83M | 9.93M | 13.52M | 16.47M | 18.18M | |
| Days sales outstanding | 46.06 | 28.53 | 30.18 | 14.3 | 35.6 | |
| Days payables outstanding | 349.78 | 157.43 | 187.85 | 529.43 | 442.53 | |
| Days of inventory on hand | 159.56 | 206.72 | 253.21 | 689.12 | 863.17 | |
| Receivables turnover | 1.95 | 3.15 | 2.98 | 6.29 | 2.53 | |
| Payables turnover | 0.26 | 0.57 | 0.48 | 0.17 | 0.2 | |
| Inventory turnover | 0.56 | 0.44 | 0.36 | 0.13 | 0.1 | |
| ROE | 0.03 | -0.08 | -0.09 | -0.1 | -0.12 | |
| Capex per share | 0 | -0.01 | 0 | -0.01 | 0 |
0HB0.L Frequently Asked Questions
What is Agios Pharmaceuticals, Inc. stock symbol ?
Agios Pharmaceuticals, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol 0HB0.L
What is Agios Pharmaceuticals, Inc. stock quote today ?
Agios Pharmaceuticals, Inc. stock price is $29.1 today.
Is Agios Pharmaceuticals, Inc. stock public?
Yes, Agios Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 522
- Market Capitalization 1.66B
- Employee 383
- CEO Mr. Brian M. Goff M.B.A.
- Headquarters Cambridge,MA,US
- IPO Date 2018-01-29
-
Website
https://www.agios.com 
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
